Beta Bionics, Inc. (BBNX) — SEC Filings
Beta Bionics, Inc. (BBNX) — 16 SEC filings. Latest: 10-Q (Oct 28, 2025). Includes 7 8-K, 3 10-Q, 3 S-1/A.
View Beta Bionics, Inc. on SEC EDGAR
Overview
Beta Bionics, Inc. (BBNX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 28, 2025: Beta Bionics, Inc. (BBNX) reported a significant increase in net sales for the three and nine months ended September 30, 2025. Net sales for the three months rose to $27.253 million from $16.705 million in the prior year, a 63% increase. For the nine months, net sales reached $68.130 million, up fro
Sentiment Summary
Across 16 filings, the sentiment breakdown is: 1 bearish, 14 neutral, 1 mixed. The dominant filing sentiment for Beta Bionics, Inc. is neutral.
Filing Type Overview
Beta Bionics, Inc. (BBNX) has filed 3 10-Q, 7 8-K, 1 10-K/A, 1 10-K, 3 S-1/A, 1 S-1 with the SEC between Jan 2025 to Oct 2025.
Recent SEC Filings (16)
Risk Profile
Risk Assessment: Of BBNX's 15 recent filings, 2 were flagged as high-risk, 8 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $68.130M |
| Net Income | ($59.734M) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $38.485M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Sean Saint
- Carlos Ramirez
- Mark Weeks
- Charles S. Kim
- Stephen Feider
- Nathan Ajiashvili
Industry Context
Beta Bionics operates in the rapidly evolving diabetes technology market, specifically focusing on automated insulin delivery systems. The competitive landscape includes established medical device companies and emerging biotech firms, all vying for market share in a sector driven by innovation and patient outcomes. Trends include the increasing adoption of connected devices and data-driven health solutions.
Top Tags
sec-filing (5) · ipo (5) · financial-reporting (4) · 8-k (4) · medical-devices (3) · Medical Devices (2) · Diabetes Management (2) · Biotechnology (2) · financials (2) · High Growth (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales (Q3 2025) | $27.253M | Increased 63% from $16.705M in Q3 2024 |
| Net Sales (YTD 2025) | $68.130M | Increased 52% from $44.684M in YTD 2024 |
| Net Loss (Q3 2025) | ($14.209M) | Worsened from ($9.736M) in Q3 2024 |
| Net Loss (YTD 2025) | ($59.734M) | Worsened from ($36.648M) in YTD 2024 |
| Sales and Marketing Expenses (YTD 2025) | $45.070M | Increased from $26.282M in YTD 2024 |
| Research and Development Expenses (YTD 2025) | $24.658M | Increased from $16.970M in YTD 2024 |
| Cash and Cash Equivalents | $38.485M | As of September 30, 2025, up from $30.432M at Dec 31, 2024 |
| Common Stock Outstanding | 44,024,631 | As of October 24, 2025 |
| Additional Paid-in Capital | $650.873M | As of September 30, 2025, significantly increased due to IPO |
| Q3 Net Sales Growth | 63% | Year-over-year increase for the three months ended September 30, 2025 |
| Net Loss | $40.2M | Increased from $28.5M in prior year period, indicating widening losses. |
| Revenue | $25.3M | Up 35.3% from $18.7M in the prior year period, showing product traction. |
| Accumulated Deficit | $450.3M | As of June 30, 2025, highlighting significant historical losses. |
| Customer Concentration (Distributor D) | 20% | Percentage of net sales for the six months ended June 30, 2025, indicating reliance. |
| R&D Expenses | $20.1M | Increased from $15.5M, reflecting continued investment in product development. |
Frequently Asked Questions
What are the latest SEC filings for Beta Bionics, Inc. (BBNX)?
Beta Bionics, Inc. has 16 recent SEC filings from Jan 2025 to Oct 2025, including 7 8-K, 3 10-Q, 3 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BBNX filings?
Across 16 filings, the sentiment breakdown is: 1 bearish, 14 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Beta Bionics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Beta Bionics, Inc. (BBNX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Beta Bionics, Inc.?
Key financial highlights from Beta Bionics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BBNX?
The investment thesis for BBNX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Beta Bionics, Inc.?
Key executives identified across Beta Bionics, Inc.'s filings include Sean Saint, Carlos Ramirez, Mark Weeks, Charles S. Kim, Stephen Feider and 1 others.
What are the main risk factors for Beta Bionics, Inc. stock?
Of BBNX's 15 assessed filings, 2 were flagged high-risk, 8 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Beta Bionics, Inc.?
Forward guidance and predictions for Beta Bionics, Inc. are extracted from SEC filings as they are enriched.